Liany Luna-Dulcey1, Rebeka Tomasin1, Marina A Naves1, James A da Silva2, Marcia R Cominetti1. 1. Laboratory of Biology of Aging, Department of Gerontology, Federal University of São Carlos, CEP 13565-905, São Carlos, SP, Brazil. 2. Department of Pharmacy, Federal University of Sergipe, CEP 49400-000, São José, Lagarto, SE, Brazil.
Abstract
Triple negative breast cancer (TNBC) is very aggressive and lacks specific therapeutic targets, having limited treatment options and poor prognosis. [6]-gingerol is the most abundant and studied compound in ginger, presenting diverse biological properties such as antitumor activity against several types of cancer, including breast cancer. In this study, we show that the semi-synthetic analogue SSi6, generated after chemical modification of the [6]-gingerol molecule, using acetone-2,4-dinitrophenylhydrazone (2,4-DNPH) reagent, enhanced selective cytotoxic effects on MDA-MB-231 cells. Remarkably, unlike the original [6]-gingerol molecule, SSi6 enabled autophagy followed by caspase-independent apoptosis in tumor cells. We found a time-dependent association between SSi6-induced oxidative stress, autophagy and apoptosis. Initial SSi6-induced reactive oxygen species (ROS) accumulation (1h) led to autophagy activation (2-6h), which was followed by caspase-independent apoptosis (14h) in TNBC cells. Additionally, our data showed that SSi6 induction of ROS plays a key role in the promotion of autophagy and apoptosis. In order to investigate whether the observed cell death induction was dependent on preceding autophagy in MDA-MB-231 cells, we used siRNA to knock down LC3B prior to SSi6 treatment. Our data show that LC3B downregulation decreased the number of apoptotic cells after treatment with SSi6, indicating that autophagy is a key initial step on SSi6-induced caspase-independent apoptosis. Overall, the results of this study show that structural modifications of natural compounds can be an interesting strategy for developing antitumor drugs, with distinct mechanisms of actions, which could possibly be used against triple negative breast cancer cells that are resistant to canonical apoptosis-inducing drugs.
Triple negative breast cancer (TNBC) is very aggressive and lacks specific therapeutic targets, having limited treatment options and poor prognosis. [6]-gingerol is the most abundant and studied compound in ginger, presenting diverse biological properties such as antitumor activity against several types of cancer, including breast cancer. In this study, we show that the semi-synthetic analogue SSi6, generated after chemical modification of the [6]-gingerol molecule, using acetone-2,4-dinitrophenylhydrazone (2,4-DNPH) reagent, enhanced selective cytotoxic effects on MDA-MB-231 cells. Remarkably, unlike the original [6]-gingerol molecule, SSi6 enabled autophagy followed by caspase-independent apoptosis in tumor cells. We found a time-dependent association between SSi6-induced oxidative stress, autophagy and apoptosis. Initial SSi6-induced reactive oxygen species (ROS) accumulation (1h) led to autophagy activation (2-6h), which was followed by caspase-independent apoptosis (14h) in TNBC cells. Additionally, our data showed that SSi6 induction of ROS plays a key role in the promotion of autophagy and apoptosis. In order to investigate whether the observed cell death induction was dependent on preceding autophagy in MDA-MB-231 cells, we used siRNA to knock down LC3B prior to SSi6 treatment. Our data show that LC3B downregulation decreased the number of apoptotic cells after treatment with SSi6, indicating that autophagy is a key initial step on SSi6-induced caspase-independent apoptosis. Overall, the results of this study show that structural modifications of natural compounds can be an interesting strategy for developing antitumor drugs, with distinct mechanisms of actions, which could possibly be used against triple negative breast cancer cells that are resistant to canonical apoptosis-inducing drugs.
Entities:
Keywords:
autophagy; breast cancer; caspase-independent apoptosis; cytotoxicity; natural products
Programed cell death (PCD) is an active process that includes a series of orchestrated signals that ultimately lead to cell death [1]. PCD can be further classified into several types; the two main ones being apoptosis and autophagy. Moreover, apoptosis can be dependent or independent on caspases and has been widely studied as a cellular response to DNA damage. However, recent studies suggest that autophagy also plays an important role in determining the final fate of the cell [2]. Although there has been extensive research on caspase-mediated cell death, much less is known about the molecular mechanisms involved in caspase-independent cell death. Caspase-independent apoptosis (CIA) is mediated by several effectors, including the apoptosis-inducing factor (AIF) [3, 4]. Upon reactive oxygen species (ROS) accumulation and apoptotic stimuli, AIF is released from the mitochondria and translocated to the nucleus, where it triggers large-scale DNA fragmentation and nuclear chromatin condensation, leading to CIA [5].Macroautophagy (autophagy hereafter) refers to the lysosomal degradation mechanism, which is in normal conditions, essential for survival, development, differentiation and cell homeostasis [6, 7]. It is well known that autophagy plays a key role in a variety of cellular processes, such as oxidative stress, metabolism and cell death/survival [8]. However, the role of autophagy in cancer remains controversial and is yet to be elucidated [9]. It has been described that in the early stages, autophagy is an important anti-cancer mechanism preventing cancer initiation [10]. On the other hand, it is believed that autophagy can support cancer progression via its pro-survival action in cells [11].Autophagy is tightly regulated by a network of upstream signaling cascades [12]. A key protein for this process is light chain 3 (LC3B), which is required for autophagosome assembling. It is commonly used to estimate the abundance of autophagosomes, and therefore, autophagy in the cells [13, 14]. Even though autophagy cell death is different from apoptosis, the complex link between them has been investigated, but is still not well understood [15]. Emerging studies report that autophagy and apoptosis can overlap in cancer cells in response to treatment [16, 17].Reactive oxygen species (ROS) are free radicals derived from oxygen metabolism [18]. ROS is known to play important roles in various biochemical processes, including apoptosis and autophagy. An excess of ROS, known as oxidative stress, can damage some organelles, which can activate cell death from both tumor and normal cells [19]. Several anti-cancer drugs have been shown to activate ROS-mediated autophagy, which in turn leads to cytoprotective regulation, as well as to activate apoptosis or both [20, 21].Triple-negative breast cancer (TNBC), which comprises 15% to 20% of all cases, is the most aggressive, and consequently, the one with the worst prognosis amongst all breast cancer subtypes. TNBC lacks expression of both estrogen and progesterone receptors (ER and PR, respectively), as well as lacks or have very low levels of human epidermal growth factor receptor 2 (HER2) [22]. Treatment for TNBC often comprises high doses of chemotherapeutic drugs and radiation. However, these options have limited efficacy and undesired side effects. In addition, tumor cells can develop resistance to therapies; therefore, selective compounds that induce PCD in cancer cells are highly nedeed.Ginger (Zingiber officinale Roscoe) is plant historically used in complementary and alternative medicine [23]. [6]-gingerol (6G) was identified as the major phenolic compound of the rhizomes of the plant. It has been described that 6G has several pharmacological effects, including antitumor activity [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process. Mini Rev Med Chem. 2014 ">24]. This work investigated the effects of SSi6, a semi-synthetic substance produced by chemical modification of 6G [25], on the induction of cell death in MDA-MB-231 cells.
RESULTS
Cytotoxicity of SSi6, 6G and acetone-2,4-DNPH
The semisynthetic substance SSi6 (Supplementary Figure 1A) was produced by chemical modification of [6]-gingerol (6G) (Supplementary Figure 1B), using the organic compound acetone-2,4-dinitrophenylhydrazine (2,4-DNPH) (Supplementary Figure 1C). Treatment of MDA-MB-231 or MCF-10A cells with SSi6 induced morphological changes; however, this effect was evident much earlier and more prominently in tumor cells, which at 2h of incubation with 50μM and over, acquired a round shape, accompanied by a loss of density (Supplementary Figure 2A). At 48h of treatment, SSi6 induced dramatic morphological changes in MDA-MB-231 cells at concentrations starting from 25μM. At this point, a total lack of adherence and the presence of cellular debris were observed, indicating cell death. On the other hand, only mild changes were observed in non-malignant cells (MCF-10A) incubated with the highest concentrations (50 and 100μM) of SSi6 and in the longest incubation time (48h) (Supplementary Figure 2B). In addition, the activity of SSi6 was tested in non-TNBC cells such as MCF-7 (ER receptor) and SKBR3 (HER2 receptor). As observed in Supplementary Figure 3, SSi6 does not induce the formation of cytoplasmic vacuoles in these cells.Cytotoxicity against MDA-MB-231, MCF-10A, MCF-7 and SKBR3 cells was evaluated and the results expressed as IC50 values are listed in Table 1. SSi6 exhibited a slightly greater cytotoxicity (IC50 22.90±0.35μM) against MDA-MB-231 in comparison to MCF-10A (IC50 34.17±2.49μM), with a selectivity index of ~1.49 for malignant cells after 48h of treatment. On the other hand, 6G exhibited IC50 values of 404.5±7.6μM for MDA-MB-231, 985.8±0.57μM for MCF-7, 316.2±0.61μM for SKBR3 and 599.4±8.5μM for MCF-10A cells, while 2,4-DNPH presented IC50 values >100μM for all cell lines, thus both 6G and 2,4-DNPH were much less active than its semi-synthetic counterpart SSi6. Therefore, according to the presented results, we demonstrated that the chemical modification performed in 6G improved approximately 17 times in the IC50 value for cytotoxicity on TNBC cells. In non-TNBC cells, MCF-7 and SKBR3 SSi6 cytotoxicity was lower compared to TNBC cells (Table 1). As shown in Supplementary Figure 3 the effects on the morphology of these same cells treated with SSi6. According to these results, SSi6 presents higher cytotoxic activity in MDA-MB-231 cells; therefore, the mechanisms of death presented hereafter will be performed in TNBC cells. The human primary dermal fibroblast (HPDF) cell line was also used to investigate SSi6 cytotoxicity (Supplementary Figure 4), showing once again that SSi6 has low cytotoxicity against non-tumor cells.
Table 1
IC50 values of 48h treatment of [6]-gingerol (6G), 2,4-DNPH and SSi6 in the MDA-MB-231, MCF-10A, MCF-7 and SKBR3 cell lines
Substances
IC50 ±SD(μM)
MDA-MB-231
MCF-10A
MCF-7
SKBR3
SIa
6G
404.5±17.6
599.4±18.5
985.8±0.57
316.2±0.61
1.48
2,4-DNPH
>100
>100
>100
>100
------
SSi6
22.90±0.35
34.17±2.49
31.01±3.2
21.93±0.67
1.49
Values are expressed as mean ± SD of three independent assays in triplicate
Values are expressed as mean ± SD of three independent assays in triplicateSD = Standard deviationa(SI) Selectivity index: IC50 MCF-10A/IC50 MDA-MB-231.Interestingly, the presence of cytoplasmic vacuoles in MDA-MB-231 cells subjected to SSi6 treatment (50 and 100μM) was evident from 2 and 6h of incubation (Figure 1A), which was not observed in non-malignant MCF-10A in the same times of treatment after 48h (Figure 1B). Neither 6G nor 2,4-DNPH evoked any changes in the cell morphology, even at the highest concentration and longest incubation time point. Wortmannin, an indirect autophagy inhibitor [26, 27], was able to completely abrogate vacuole formation (Figure 1A), indicating that SSi6-induced cytoplasmic vacuoles are probably linked to the occurrence of autophagy in these cells.
Figure 1
Effects of SSi6 and 6G on morphology and colony formation of triple negative breast cancer MDA-MB-231 cells
(A) Detection of cytoplasmic vacuoles in MDA-MB-231 after incubation with SSi6 for 2 and 6h (yellow arrows). Cells were examined using an inverted microscope (amplification 200×), scale bar = 50μm. (B) As a control, non-tumorMCF-10A cells treated (2, 6 and 48h) with SSi6 at the same conditions did not present cytoplasmic vacuoles, even at high concentrations and longer incubation time (48h). (C) Clonogenic assay of MDA-MB-231 cells treated with indicated concentrations of SSi6 and 6G for 48h. A photography of Petri-dishes from a representative experiment is shown with graph quantifications of colony number (*p<0.0001) and size (*p<0.05). Data represent mean ± SD of three independent tests in triplicate. Results were compared using ANOVA, followed by a Tukey's post-hoc analysis.
Effects of SSi6 and 6G on morphology and colony formation of triple negative breast cancer MDA-MB-231 cells
(A) Detection of cytoplasmic vacuoles in MDA-MB-231 after incubation with SSi6 for 2 and 6h (yellow arrows). Cells were examined using an inverted microscope (amplification 200×), scale bar = 50μm. (B) As a control, non-tumorMCF-10A cells treated (2, 6 and 48h) with SSi6 at the same conditions did not present cytoplasmic vacuoles, even at high concentrations and longer incubation time (48h). (C) Clonogenic assay of MDA-MB-231 cells treated with indicated concentrations of SSi6 and 6G for 48h. A photography of Petri-dishes from a representative experiment is shown with graph quantifications of colony number (*p<0.0001) and size (*p<0.05). Data represent mean ± SD of three independent tests in triplicate. Results were compared using ANOVA, followed by a Tukey's post-hoc analysis.Clonogenic assay is an in vitro cell survival experiment based on the ability of a single cell to grow into a colony, and it is used to evaluate the reproductive capacity of cells after exposure to cytotoxic agents [28]. When compared to negative control (DMSO 1%), SSi6 at 6.25, 12.5 and 15μM significantly reduced the number and size of TNBC colonies in a concentration-dependent fashion. The highest concentration (15μM) was sufficient to completely impair colony formation. In contrast, when cells were treated with 6G there was no significant inhibition in either the number or in the size of MDA-MB-231 colonies (Figure 1C).
SSi6 induces ROS generation, autophagy and caspase-independent apoptosis
In order to elucidate the underlying mechanisms involved in SSi6-induced cell death, we estimated the changes in the ROS levels in SSi6, 6G and 2,4-DNPH-treated cells using a H2DCFDA reagent. As shown in Figure 2A and 2B, there was a significant increase in the fluorescent content in MDA-MB-231 cells after 1 and 8 hours of SSi6 treatment, reflecting the accumulation of ROS in these cells. On the other hand, 6G and 2,4-DNPH did not cause generation of ROS in TBNC cells. N-acetylcysteine (NAC) is an antioxidant that replenishes intracellular glutathione (GSH) protecting the cells from oxidative stress [29]. We used the antioxidant NAC to further confirm whether SSi6 treatment was responsible for the increase in ROS. Co-treatment of NAC significantly blocked the generation of ROS in both treatment times (1 and 8h). In MCF-10A cells, ROS levels were not significant after the treatment with SSi6, 6G and 2,4-DNPH, which explains the low cytotoxic effects of SSi6 on non-tumor cells (Figure 2C and 2D). It was also demonstrated that SSi6-induced ROS production resulted in a partial mitochondrial membrane depolarization (Figure 2E).
Figure 2
Effects of SSi6 in ROS formation and mitochondrial membrane potential
MDA-MB-231 cells were treated with indicated concentrations of SSi6, 6G and 2,4-DNPH with or without NAC (5mM) for (A) 1 and (B) 8h followed by incubation with H2DCFDA. MCF-10A cells were treated with SSi6, 6G and 2,4-DNPH for (C) 1 and (D) 8h and analyzed by fluorescence. Data are presented as mean ± SD (n=3 in each group). *p<0.01, **p<0.001 vs control group using ANOVA followed by a Tukey's post-hoc analysis. (E) Loss of mitochondrial membrane potential (Δψm) induced by SSi6 is concentration and time-dependent. Δψm depolarization was monitored by flow cytometric analysis of JC-1 mitochondrial potential marker. MDA-MB-231 cells treated with indicated concentrations of SSi6 for 8h and stained with JC-1 as described in material and methods. Camptothecin (200μM) was used as positive control (apoptosis induction agent). Gated region R1 (red) includes cells with intact mitochondrial membranes and gated region R2 (green) depicts cells with loss of Δψm. Graphic representation of mean values for R2 region data (cells with Δψm collapse). Data represents mean ± SD of three independent assays in triplicate. Significance at the **p<0.001, ***p<0.0001 level using ANOVA followed by a Tukey's post-hoc analysis.
Effects of SSi6 in ROS formation and mitochondrial membrane potential
MDA-MB-231 cells were treated with indicated concentrations of SSi6, 6G and 2,4-DNPH with or without NAC (5mM) for (A) 1 and (B) 8h followed by incubation with H2DCFDA. MCF-10A cells were treated with SSi6, 6G and 2,4-DNPH for (C) 1 and (D) 8h and analyzed by fluorescence. Data are presented as mean ± SD (n=3 in each group). *p<0.01, **p<0.001 vs control group using ANOVA followed by a Tukey's post-hoc analysis. (E) Loss of mitochondrial membrane potential (Δψm) induced by SSi6 is concentration and time-dependent. Δψm depolarization was monitored by flow cytometric analysis of JC-1 mitochondrial potential marker. MDA-MB-231 cells treated with indicated concentrations of SSi6 for 8h and stained with JC-1 as described in material and methods. Camptothecin (200μM) was used as positive control (apoptosis induction agent). Gated region R1 (red) includes cells with intact mitochondrial membranes and gated region R2 (green) depicts cells with loss of Δψm. Graphic representation of mean values for R2 region data (cells with Δψm collapse). Data represents mean ± SD of three independent assays in triplicate. Significance at the **p<0.001, ***p<0.0001 level using ANOVA followed by a Tukey's post-hoc analysis.To confirm the nature of the cytoplasmic vacuoles previously observed in the morphology assay, a test for acid vesicular organelles (AVOs) detection was carried out using acridine orange [30]. Rapamycin (500nM), an inductor of autophagy, was used as a positive control (24h incubation). SSi6 induced, in a concentration-dependent manner, the occurrence of AVOs in MDA-MB-231 cells after 6h of treatment, shown by a strong red fluorescence in the cytoplasm, which was absent in non-malignant MCF-10A cells (Figure 3A). In addition, an immunostaining assay was performed to detect LC3B, a protein that is considered an autophagy marker [12, 31]. Similarly, the induction of autophagy was clear after 6h of SSi6 (50μM) treatment in MDA-MB-231 cells but was absent in non-malignant MCF-10A cells (Figure 3B). In contrast, 6G (100μM) did not evoke LC3B expression in malignant or in non-malignant cells. When wortmannin, an indirect autophagy inhibition control [27], was previously incubated with SSi6 (30μM wortmannin + 50μM SSi6) there was a block in the synthesis of LC3B protein (Figure 3B). Overall, these data indicate that SSi6 is a potent inducer of autophagy in TNBC cells, after relatively short incubation times (2-6h). It is important to mention that SSi6 leads to vacuole formation only up to 6 hours of treatment. After that, changes in cell morphology and density can be observed in 14-24h of treatment.
Figure 3
Effects of SSi6 and 6G on induction of autophagy
(A) MDA-MB-231 and MCF-10A cells were treated with indicated concentrations of SSi6 and 6G for 6h. Rapamycin 500nM for 24h was used as a positive control of autophagy. Cells were fixed, stained with acridine orange (AO) and images were captured with ImageXpress micro, detecting the formation of acid vesicular organelles (AVOs). Nuclei were stained with DAPI, scale bar = 50 μm. (B) MDA-MB-231 and MCF-10A were treated with SSi6 (50μM) and 6G (100μM) for 6h. Cells were incubated with anti-LC3B and Alexa fluor 488®. Wortmannin was used as an inhibitor of autophagy, previously to the treatment with SSi6 (Wort 30μM + 50μM of SSi6). Images were obtained with amplification of 400×. White arrows indicate the labeling of the LC3B protein after incubation of rapamycin and SSi6 for 24 and 6h, respectively.
Effects of SSi6 and 6G on induction of autophagy
(A) MDA-MB-231 and MCF-10A cells were treated with indicated concentrations of SSi6 and 6G for 6h. Rapamycin 500nM for 24h was used as a positive control of autophagy. Cells were fixed, stained with acridine orange (AO) and images were captured with ImageXpress micro, detecting the formation of acid vesicular organelles (AVOs). Nuclei were stained with DAPI, scale bar = 50 μm. (B) MDA-MB-231 and MCF-10A were treated with SSi6 (50μM) and 6G (100μM) for 6h. Cells were incubated with anti-LC3B and Alexa fluor 488®. Wortmannin was used as an inhibitor of autophagy, previously to the treatment with SSi6 (Wort 30μM + 50μM of SSi6). Images were obtained with amplification of 400×. White arrows indicate the labeling of the LC3B protein after incubation of rapamycin and SSi6 for 24 and 6h, respectively.To further characterize the type of cell death involved in the cytotoxic effects observed in MDA-MB-231, cells were incubated with SSi6 or 6G for 6 or 14h, stained with PE-Annexin-V and 7-AAD, and analyzed by flow cytometry (Figure 4A). At 6h of treatment, there was no significant occurrence of apoptosis in either 6G or SSi6-treated MDA-MB-231 cells compared to untreated controls. On the other hand, after 14h of treatment with SSi6 (100μM), there was a remarkable increase in the percentage of apoptotic cells, indicating that the initial events of autophagy (2-6h) were followed by apoptotic cell death (14h) upon incubation with SSi6. After 14h of incubation with SSi6 at 100μM the percentage of TNBC cells in apoptosis was 39.5%, while after the same time and concentration, 6G induced 20.9% of apoptosis. In fact, this difference does not appear to be very significant, however if we analyze the effects on autophagy, as demonstrated by cellular morphology with the presence of high amounts of vacuoles and by the formation of acid vesicles, SSi6 was much more effective inducing autophagy compared to 6G. In this sense, it seems that the most important effect of adding 2,4-DNPH to 6G is the induction of autophagy.
Figure 4
Effects of SSi6 and 6G in apoptosis and expression of apoptosis- and autophagy-related genes in TNBC cells
(A) Cytometry analysis of MDA-MB-231 cells treated with indicated concentrations of SSi6 and 6G for 6 and 14h, respectively. Camptothecin (200μM) was used as positive control of apoptosis (treatment for 24h). Data represents mean ± SD of three independent assays in triplicate. Significance at the *p<0.001, **p<0.0001 level using ANOVA followed by a Tukey's post-hoc analysis. (B) Cells were incubated with indicated concentrations of SSi6 and 6G for two different times and in independent assays: 1h-6G, 1h-SSi6 and 10h-SSi6 to determine LC3B gene expression and (C) 10h-6G, 1h-SSi6 and 10h-SSi6 to evaluate expression of the CASP3 and (D) AIF genes. Negative control (C-) represents cells with no treatment. Total RNA was extracted and cDNAs were synthesized. Amplification of endogen control (Rpl37a) and each of the target genes was performed using real-time PCR equipment. Data represent mean ± SD of three independent assays in triplicate. Results were compared using ANOVA, followed by a Tukey's post-hoc analysis. Significance at the *p<0.05, **p<0.001, #p<0.01, ##p<0.001 vs negative control in the respective time.
Effects of SSi6 and 6G in apoptosis and expression of apoptosis- and autophagy-related genes in TNBC cells
(A) Cytometry analysis of MDA-MB-231 cells treated with indicated concentrations of SSi6 and 6G for 6 and 14h, respectively. Camptothecin (200μM) was used as positive control of apoptosis (treatment for 24h). Data represents mean ± SD of three independent assays in triplicate. Significance at the *p<0.001, **p<0.0001 level using ANOVA followed by a Tukey's post-hoc analysis. (B) Cells were incubated with indicated concentrations of SSi6 and 6G for two different times and in independent assays: 1h-6G, 1h-SSi6 and 10h-SSi6 to determine LC3B gene expression and (C) 10h-6G, 1h-SSi6 and 10h-SSi6 to evaluate expression of the CASP3 and (D) AIF genes. Negative control (C-) represents cells with no treatment. Total RNA was extracted and cDNAs were synthesized. Amplification of endogen control (Rpl37a) and each of the target genes was performed using real-time PCR equipment. Data represent mean ± SD of three independent assays in triplicate. Results were compared using ANOVA, followed by a Tukey's post-hoc analysis. Significance at the *p<0.05, **p<0.001, #p<0.01, ##p<0.001 vs negative control in the respective time.mRNA and protein expression levels of autophagy and apoptosis-related genes were accessed in SSi6-treated TNBC cells. LC3B mRNA was upregulated after 1h of incubation with SSi6; however, the levels returned to normal after 10h of incubation (Figure 4B). On the other hand, after 1h of treatment with SSi6 there was no positive CASP-3 gene regulation. Nevertheless, after 10h this gene had its expression positively regulated compared to the control (Figure 4C). Regarding the AIF mRNA expression, while no significant changes were observed after 1hSSi6 incubation, there was a significant upregulation at 10h of treatment (Figure 4D). Neither of these alterations were observed when the treatments were conducted using 6G, which is in agreement with our previous assays indicating that 6G did not induce autophagy and had only mild apoptotic effects in TNBC cells at these conditions.We have also examined changes in LC3B protein levels upon SSi6, 6G and 2,4-DNPH treatment. Conversion of LC3B-I into its lipidated form at the C-terminal end (LC3B-II) is regarded as a key marker of autophagy [32]. SSi6 markedly increased the lipidation of LC3B (LC3B-II) in a concentration and time-dependent manner in MDA-MB-231 cells (Figure 5A and 5B). The co-treatment of TNBC with SSi6 (100μM) and wortmannin (30μM) abolished the induction of autophagy, as demonstrated by the reduced levels of LC3B-II, which corroborates the results found in RT-qPCR, again indicating the occurrence of autophagy. As expected, 6G and 2,4-DNPH had no effect on LC3B levels in TNBC cells (Figure 5A and 5B).
Figure 5
Effects of SSi6, 6G and 2,4-DNPH on the levels of apoptosis- and autophagy-related proteins in TNBC cells
(A) MDA-MB-231 cells were treated with indicated concentrations of SSi6, 6G and 2,4-DNPH for 3 and 6h. Cells were then harvested and subjected to western blot analysis of LC3B (LC3B-I and LC3B-II) protein. (B) Protein expression was quantified using ImageJ software, means ± SD were presented (*p<0.05; **p<0.01, Tukey's post-hoc analysis). (C) MDA-MB-231 cells were harvested after treatment with indicated concentrations of SSi6 and 6G for the indicated period of time, the western blot was then performed for the detection of caspase-3 (pro-casp3 and cleaved casp3). β-actin was used a endogen control. (D) Protein expression was quantified using ImageJ software, means ± SD were presented (*p<0.05, Tukey's post-hoc analysis). (E) Cells were treated with indicated concentrations of SSi6 and 6G for 14h, followed by western blot to detect AIF (caspase-independent apoptosis marker). (F) Protein expression was quantified using ImageJ software, means ± SD were presented (**p<0.001, Tukey's post-hoc analysis). The controls performed corresponded to the C- (negative control-DMSO 1%), C+ (positive control of autophagy induction-rapamycin 500nM-24h) and Wort + SSi6 (control of autophagy inhibition - 30μM wortmannin + 100μM SSi6-6h).
Effects of SSi6, 6G and 2,4-DNPH on the levels of apoptosis- and autophagy-related proteins in TNBC cells
(A) MDA-MB-231 cells were treated with indicated concentrations of SSi6, 6G and 2,4-DNPH for 3 and 6h. Cells were then harvested and subjected to western blot analysis of LC3B (LC3B-I and LC3B-II) protein. (B) Protein expression was quantified using ImageJ software, means ± SD were presented (*p<0.05; **p<0.01, Tukey's post-hoc analysis). (C) MDA-MB-231 cells were harvested after treatment with indicated concentrations of SSi6 and 6G for the indicated period of time, the western blot was then performed for the detection of caspase-3 (pro-casp3 and cleaved casp3). β-actin was used a endogen control. (D) Protein expression was quantified using ImageJ software, means ± SD were presented (*p<0.05, Tukey's post-hoc analysis). (E) Cells were treated with indicated concentrations of SSi6 and 6G for 14h, followed by western blot to detect AIF (caspase-independent apoptosis marker). (F) Protein expression was quantified using ImageJ software, means ± SD were presented (**p<0.001, Tukey's post-hoc analysis). The controls performed corresponded to the C- (negative control-DMSO 1%), C+ (positive control of autophagy induction-rapamycin 500nM-24h) and Wort + SSi6 (control of autophagy inhibition - 30μM wortmannin + 100μM SSi6-6h).Once our data indicated that apoptosis is a later event in SSi6-induced toxicity, AIF and caspase-3 protein levels were accessed after 14h of treatment, however no cleaved caspase-3 expression was detected (Figure 5C and 5D). An important point is that the measurement of caspase-3 was performed in 19, 24 and 28 hours of treatment, showing the same result in all analyzed times (data not shown). In the other hand, AIF levels increased upon treatment, especially with SSi6 (Figure 5E and 5F), indicating the involvement of a caspase-independent mechanism on apoptosis induction by SSi6 in TNBC cells.
SSi6 inhibits autophagic flux in MDA-MB-231 cells
Lysosomal degradation of autophagosomes leads to a decrease in LC3B-II levels during autophagy [32]. Blockage of autophagic flux correlates with increased levels of LC3B-II, which contributes to cell death [33, 34]. Our data showed that SSi6 markedly increased the lipidation of LC3 (LC3B-II) in a concentration-dependent manner (Figure 6A and 6B). In addition, the blockage of autophagosomal degradation induced by chloroquine (CQ), an indirect autophagy inhibitor, caused time-dependent (Figure 6C and 6D) LC3B-II accumulation, indicating a decrease in autophagic flux [27, 32].
Figure 6
SSi6 increases autophagic flux and induces autophagy and apoptosis via the activation ROS production
(A) MDA-MB-231 cells were treated with the indicated concentrations of SSi6 with or without chloroquine (CQ, 50μM) for 6h. Cell lysed were collected to western blotting for detecting LC3 conversion. (B) LC3B-II expression was evaluated by ImageJ software, means ± SD were presented (*p<0.01; **p<0.001, Tukey's post-hoc analysis). (C) Cells were treated with SSi6 (100μM) for the indicated time points with or without CQ (50μM). (D) Protein levels (LC3B-II) was analyzed by ImageJ software, means ± SD were presented (**p<0.0001, Tukey's post-hoc analysis). β-actin was used as a loading control. (E) MDA-MB-231 cells were treated with SSi6 (50 and 100μM) with or without NAC (5mM) for 6h. Cells lysates were analyzed by western blotting for detecting LC3B-II. β-actin was used as endogen control. (F) The levels of LC3B-II were analyzed by ImageJ software, means ± SD were presented (**p<0.0001, Tukey's post-hoc analysis). (G) Cells were treated with SSi6 (50 and 100μM) for 7h, then treated with NAC (5mM) for additional 7h, and analyzed by cytometry using 7AAD and Annexin-V. Camptothecin (200μM) was used as positive control of apoptosis. (H) The apoptotic rate was determined by fluorescence intensity using flow cytometry. Results are presented as mean ±SD from three independent experiments (**p<0.001 vs control group, Tukey's post-hoc analysis).
SSi6 increases autophagic flux and induces autophagy and apoptosis via the activation ROS production
(A) MDA-MB-231 cells were treated with the indicated concentrations of SSi6 with or without chloroquine (CQ, 50μM) for 6h. Cell lysed were collected to western blotting for detecting LC3 conversion. (B) LC3B-II expression was evaluated by ImageJ software, means ± SD were presented (*p<0.01; **p<0.001, Tukey's post-hoc analysis). (C) Cells were treated with SSi6 (100μM) for the indicated time points with or without CQ (50μM). (D) Protein levels (LC3B-II) was analyzed by ImageJ software, means ± SD were presented (**p<0.0001, Tukey's post-hoc analysis). β-actin was used as a loading control. (E) MDA-MB-231 cells were treated with SSi6 (50 and 100μM) with or without NAC (5mM) for 6h. Cells lysates were analyzed by western blotting for detecting LC3B-II. β-actin was used as endogen control. (F) The levels of LC3B-II were analyzed by ImageJ software, means ± SD were presented (**p<0.0001, Tukey's post-hoc analysis). (G) Cells were treated with SSi6 (50 and 100μM) for 7h, then treated with NAC (5mM) for additional 7h, and analyzed by cytometry using 7AAD and Annexin-V. Camptothecin (200μM) was used as positive control of apoptosis. (H) The apoptotic rate was determined by fluorescence intensity using flow cytometry. Results are presented as mean ±SD from three independent experiments (**p<0.001 vs control group, Tukey's post-hoc analysis).
Role of ROS in the promotion of autophagy and apoptosis by SSi6
Considering that ROS are involved in the induction of both processes (autophagy and apoptosis) [35, 36], it was necessary to investigate whether ROS blockade would affect the activation of these cell death processes. To determine how much of the total autophagy rate was linked to ROS; MDA-MB-231 cells were co-treated with NAC (5mM) for 6h. Western blotting analysis showed that there was a significant reduction in the level of LC3B isoforms (Figure 6E and 6F). Next, the role of ROS generation in SSi6-induced apoptosis was investigated. In this case, the NAC (5mM) was added only after 7h to the cells to not affect the initial induction of autophagy, subsequently the apoptotic rate was measured at 14h by flow cytometry. After this time, the apoptotic rate decreased significantly, evidencing as in the previous case, the connection of this process with ROS (Figure 6G and 6H). In SSi6-treated MDA-MB-231 cells, the apoptotic rate, at the same incubation time and at 100μM, was 39.5% (see Figure 4A). Taken together, the results indicate that ROS generation by SSi6 participates in the induction of autophagy and apoptosis.
LC3B knockdown attenuates SSi6 apoptotic effects in TNBC cells
Finally, to demonstrate the importance of autophagy in the SSi6-induced caspase-independent apoptosis, LC3B in MDA-MB 231 cells were knocked down using siRNA. Was investigated whether LC3B knockdown would influence cell death upon SSi6 treatment. Indeed, LC3B silencing remarkably reduced SSi6-induced apoptosis in MDA-MB 231 cells (Figure 7A). LC3B-mediated autophagy is a well described mechanism in the literature. LC3B levels after 48, 72 and 96h of transfection demonstrated a silencing efficacy for both siRNA sequences used (si-48 and si-86) (Figure 7B). SSi6 treatment was unable to rescue the expression of LC3B protein in silenced cells (Supplementary Figure 5). Next it was analyzed whether the knockdown of the LC3B was associated with the reduction of AIF. The accumulation of free radicals upon SSi6 treatment induced partial loss of Δψm (see Figure 2C) leading to the release of apoptosis effector proteins located in the mitochondrial matrix, such as AIF, towards the cytoplasm. Furthermore, LC3B knockdown significantly reduced SSi6-mediated AIF expression in MDA-MB-231 cells (Figure 7C). Taken together, these data indicate that, at least to some extent, SSi6-induced apoptosis in TNBC cells strongly relies on prior autophagy events that were inhibited upon LC3B silencing.
Figure 7
LC3B knockdown attenuates SSi6 apoptotic effects in TNBC cells
(A) MDA-MB-231 cells were transfected with siRNA targeting LC3B or non-target siRNA (NT). (A) Suppression of autophagy partially inhibits apoptosis in MDA-MB-231 cells. Cells were treated with indicated concentrations of SSi6 for 24h, fixed and stained with PE-Annexin-V and 7-AAD. The si-86 was the siRNA with the higher effect on apoptosis (sum of the percentage of early and late apoptotic cells) and is represented by an orange arrow in histograms. Data represents mean ± SD of three independent assays in triplicate. Significance at the *p<0.05, **p<0.001 level using ANOVA followed by a Tukey's post-hoc analysis. NT: non-target control #1 siRNA; si-48: MAP1LC3B silencer siRNA-ID: s37748; si-86: MAP1LC3B silencer siRNA-ID: s224886. (B) LC3B (LC3B-I and LC3B-II) and (C) AIF expression was analyzed by western blotting after 48, 72, 96 and 14h respectively. β-actin was used as endogen control.
LC3B knockdown attenuates SSi6 apoptotic effects in TNBC cells
(A) MDA-MB-231 cells were transfected with siRNA targeting LC3B or non-target siRNA (NT). (A) Suppression of autophagy partially inhibits apoptosis in MDA-MB-231 cells. Cells were treated with indicated concentrations of SSi6 for 24h, fixed and stained with PE-Annexin-V and 7-AAD. The si-86 was the siRNA with the higher effect on apoptosis (sum of the percentage of early and late apoptotic cells) and is represented by an orange arrow in histograms. Data represents mean ± SD of three independent assays in triplicate. Significance at the *p<0.05, **p<0.001 level using ANOVA followed by a Tukey's post-hoc analysis. NT: non-target control #1 siRNA; si-48: MAP1LC3B silencer siRNA-ID: s37748; si-86: MAP1LC3B silencer siRNA-ID: s224886. (B) LC3B (LC3B-I and LC3B-II) and (C) AIF expression was analyzed by western blotting after 48, 72, 96 and 14h respectively. β-actin was used as endogen control.
DISCUSSION
Clinical cancer therapies comprise physical treatment such as radiotherapy and surgery, as well as chemical treatment [37]. However, the outcome of these approaches is not always satisfactory, especially when tumor cells develop resistance to canonical apoptosis-inducing drugs. Some patients are not even sensitive to the existing chemotherapeutics [38]. Therefore, it is a matter of urgency to discover more pharmacologically active compounds, which can also be used as leading compounds for structural modifications in drug development.The biological and pharmacological properties of some ginger derived compounds have already been well described in the literature. Gingerols (mainly 6G) are identified as the major constituents of plant rhizomes. In this study, 6G was chemically modified by conjugation to 2,4-DNPH in order to obtain a new semisynthetic compound, SSi6 [25]. There are no studies demonstrating the cytotoxic effects of this new substance, thus its effects were analyzed based on previous work that evaluated 6G cytotoxic and antitumor activities. These studies reported that 6G inhibited proliferation of A531 human squamous carcinoma (IC50 300μM) [39], colon HCT-116 (IC50 160.42μM) [40], hepatic HepG2 (IC50 420μM) [41] and TBNC MDA-MB-231 cells (IC50 684.3μM) [42]. In the present work, we demonstrated that the synthetic modification performed on 6G significantly increased its cytotoxicity against MDA-MB-21 cells approximately 17-fold, compared to the values shown for 6G.Numerous studies report that apoptosis and autophagy may be concomitantly induced by antitumor compounds in order to kill tumor cells in a complex, coordinated and cooperative manner [43, 44]. Other studies have demonstrated that autophagy induction is an early event, detected within the first hours of treatment, with subsequent induction of apoptosis at longer incubation time [45]. Carnosol, a phenolic diterpene with reported antioxidant activity, induced autophagy within the first 3h of treatment, confirmed by the increase in LC3B protein levels, and subsequently caused apoptosis at longer treatment times, shown by PARP cleavage in MDA-MB-231 [46]. A recent study by Wong and co-workers [47] showed that 1,3-dibutyl-2-thiooxo-imidazolidine-4,5-dione (C1) triggers intracellular ROS production, simultaneously inducing autophagy and apoptosis in several types of tumor cells, including MDA-MB-231.In agreement with these previous studies, our data showed that short-term incubation (2-6h of treatment) with SSi6 at 50 and 100μM induces autophagy in TNBC cells, which was initially observed by the occurrence of abundant cytoplasmic vesicles, characteristic of this type of cell death. In accordance with the hypothesis that SSi6 triggered autophagy, we then demonstrated that the vesicles observed upon SSi6 short-term treatment (2-6h) were AVOs, once again indicating autophagy occurrence. LC3B protein, a marker of autophagosome occurrence (and therefore autophagy), was also detected by immunostaining of SSi6-treated MDA-MB-231 cells at the same time points (2-6h). Apoptosis, accessed by flow cytometry, was not detected at 6h of SSi6 incubation but did occur at longer incubation times (24h). Accordingly, while after 1h of incubation SSi6 positively regulated LC3B gene expression and no changes were observed in hAIF (effector of apoptosis), upon 10h of SSi6 incubation, LC3B gene expression levels were back to normal and there was a significant upregulation on hAIF. These results corroborate the aforementioned literature and the hypothesis that SSi6 induces early autophagy that eventually culminates in apoptosis.ROS accumulation increases oxidative damage, which leads to an increase in autophagy [20, 48] and causes a gradual loss of mitochondrial membrane polarization [45], which changes permeability properties and ultimately allows pro-apoptotic proteins, such as AIF, to be released into the cytoplasm. Apoptosis induction by SSi6 can be explained by the fact that as incubation time increases, the damage caused by autophagy and DNA fragmentation leads to the progression of cell death to apoptosis. In other words, when apoptosis became unrestrained, as observed after SSi6 treatment, not only autophagy will lead to cell death, but also the accumulation of ROS will induce partial/gradual mitochondrial membrane depolarization and AIF release, important features during caspase-independent cell death [49]. In the present study, SSi6 induced a significant increase in ROS generation, while pretreatment with NAC remarkably reversed the SSi6-induced inhibition of the autophagy and apoptosis in MDA-MB-231 cells.Western blotting assays were performed to confirm the increase in apoptotic and autophagic protein levels in MDA-MB-231 cells exposed to SSi6. Alongside our results on gene expression, LC3B was upregulated upon 3 and 6h of SSi6 treatment, with AIF protein levels increasing at 14h of SSi6 treatment. Neither of these changes was observed in 6G and 2,4-DNPH-treated cells. These results are somehow consistent with what is described in the literature on 6G [42], although it was described that 6G promotes cell death in MDA-MB-231 cells by caspase-dependent apoptosis [50]. In particular, the 6G concentrations used to achieve such results were higher than the ones we tested [50], which could explain why it was not observed any changes in caspase-3 activation in 6G treated cells. Our results, however, demonstrated that SSi6 did not induce caspase-3 cleavage, the main effector protein in caspase-dependent apoptosis. Overall, these assays enable to demonstrate that SSi6 promotes apoptosis primarily through the induction of caspase-independent cell death, shown by a significant increase in AIF and a lack of cleaved caspase-3 protein expression.Different studies in the literature suggest that autophagic flux plays an important role in pathological processes [51]. Autophagic flux is determined by the equilibrium between autophagosome formation and autophagosome clearance by lysosomes. Thus, defects in autophagy early or late steps cause autophagic dysfunction, which subsequently induces autophagic cell death. Xu et al. [52] found that physapubescin B (pB), a steroidal compound extracted from Physalis pubescens, combined with CQ depletion the autophagic flux in human colon carcinoma HCT116 cells, demonstrating that the anticancer potential of pB can be improved when combined with autophagy inhibitors. Moreover, the study of Qiu and colleagues [53] reported that tetrandrine (Tet:10μM), a natural product isolated from the root of Stephania tetranda, blocks autophagic flux in human prostate adenocarcinoma PC-3 and human renal adenocarcinoma 786-O cells, shown by the increase of LC3-II and SQSTM1/p62 when concomitantly treated with CQ (10μM) for 1h. Our results showed that SSi6 decrease autophagic flux when combined with CQ, causing an accumulation of LC3B-II, by inhibiting the degradation of autophagosomes, leading to subsequent induction of apoptotic cell death.Wang et al. [54] found that berberine, an isoquinoline alkaloid derived from plants, decreased colony formation and induced caspase-independent cell death in the IMCE colon tumor cell line. The authors reported that the mechanism underlying berberine-induced cell death was through ROS-production-dependent AIF activation. Moreover, another study showed that dioscin, a saponin extracted from the roots of Polygonatum zanlanscianense, induced cell death via AIF-facilitating caspase-independent pathway, as well as down-regulation of anti-apoptotic proteins, such as Bcl-2 and cIAP-1 (Cellular Inhibitor of Apoptosis Protein 1) in breast cancer cells (MDA-MB-231, MDA-MB-453) [55]. Indeed, many polyphenols from natural sources have being reported to evoke autophagy and/or apoptosis in cancer cells. Concerning this, all results obtained in this work indicate that autophagy cell death is an important step that precedes apoptosis in the MDA-MB-231 cell line.Finally, in order to elucidate whether SSi6-induced autophagy was a mandatory step for downstream apoptosis induction, we knocked down LC3B, one of the main proteins involved in autophagy, in MDA-MB 231 cells prior treatment with SSi6. Indeed, apoptosis occurrence, accessed by flow cytometry, was significantly decreased in siRNA-LC3B cells, compared to non-target control (siRNA-NT) cells upon SSi6 treatment. Accordingly, AIF protein levels did not increase (and were even downregulated) upon SSi6 treatment when LC3B was knocked down. However, autophagy, and consequently apoptosis, were not completely abrogated upon treatment with SSi6 when LC3B was knocked down, as other LC3 family members (mainly LC3A-II) can also be involved in autophagy [56]. These results strongly support the hypothesis that autophagy is a key initial step in SSi6-induced caspase-independent apoptosis. A previous study has also shown that 6G has the ability to induce autophagy and apoptosis in HeLa cells. In these cells, 6G induced several morphological changes, including phosphatidylserine externalization, DNA degradation, increased TUNEL positivity, PARP and caspase-3 expression and depolarization of mitochondrial membrane, showing evidence of mitochondrial-mediated apoptosis. On the other hand, death by autophagy induced by 6G was shown by fluorescence microscopy and flow cytometry at concentrations of 75, 100 and 125μg/ml after 24h of treatment [57]. Nevertheless, to the best of our knowledge, our research is the first to report a temporal and compulsory association between autophagy and apoptosis triggered by a ginger-derived substance in MDA-MB-231 cells.In summary, this work reported that SSi6, a semisynthetic substance derived from 6G, increased ROS levels in human TNBC cells (MDA-MB-231), which triggered short-term autophagy and long-term caspase-independent apoptosis. The activation of these two mechanisms of cell death by SSi6 would be a promising strategy for breast cancer therapy, especially for cells that are resistant to canonical apoptosis-inducing agents, providing novel therapeutic tools and ultimately leading to new therapeutic strategies for cancer treatment.
MATERIALS AND METHODS
Reagents
SSi6 was obtained as described earlier [25] and dissolved in DMSO. We used the following reagents in our experiments: Acetone-2,4-dinitrophenylhydrazone (2,4-DNPH) was obtained by reaction between 2,4-dinitrophenylhydrazone and acetone, using the same methodology carried out to obtain of SSi6. 1HNMR analyses were performed for confirmation of their chemical structure. The final concentrations of Dimethyl sulfoxide (DMSO; Sigma-Aldrich, D4540) in the culture medium did not exceed 1%. The following reagents were used: DharmaFECT 4 (GE Healthcare, T-2004-01), acridine orange (catalog number A6014), rapamycin (catalog number R8781), wortmannin (catalog number W1628), propidium iodide (catalog number P4170), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; catalog number M21281G), camptothecin (catalog number C9911), SYBR Green JumpStart Taq Ready Mix (catalog number S4438), RNaseA (catalog number R6513), 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI; catalog number D9542), 2′,7′-Dichlorodihydrofluorescein diacetate (H2DCFDA; catalog number D6883), Hydrogen peroxide (H2O2; catalog number H1009), Chloroquine (CQ; catalog number C6628), N-Acetyl-L-cysteine (NAC; catalog number A9165), CelLytic™ M (catalog number C2978) were purchased from Sigma-Aldrich. For western blot analysis, the following primary and secondary antibodies were used: anti-LC3B (Abcam, ab51520), anti-caspase-3 (Abcam, ab13847) and anti-AIF (Santa Cruz Biotechnology, sc-9416), HRP-conjugated goat rabbit secondary antibody (Abcam, ab6721). For immunostaining assay the anti-rabbit Alexa Fluor 488-conjugated antibody (Thermo Scientific, D12371) was used. The BD™ MitoScreen Kit and Apoptosis Detection Kit were obtained from BD Bioscience. The LC3B silencer siRNAs (s37748, s224886) and the non-target control (AM4611) were from Thermo Scientific.
Cell culture
Non-malignant breast cells MCF-10A were cultured in Dulbecco's Modified Eagle Medium F12 (DMEM/F12; Thermo Scientific, 11320033) supplemented with 5% of horse serum (Sigma-Aldrich, H1270), 20ng/mL of Epidermal Growth Factor (EGF; Thermo Scientific, PHG0311), 0.5μg/mL of hydrocortisone (Sigma-Aldrich, H0888) 10μg/ml of insulin (Thermo Scientific, 12585-014) and 1% of penicillin/streptomycin (Vitrocell, 000403). TNBC MDA-MB-231 cells were cultured in DMEM supplemented with 10% of Fetal Bovine Serum (FBS) and appropriate antibiotics. Both cell lines were obtained from the Rio de Janeiro Cell Bank (BCRJ) and maintained at 37°C in an incubator with 95% of relative humidity and 5% CO2.
Cytotoxicity assays
The effects of 6G, 2,4-DNPH and SSi6 on the cytotoxicity of MDA-MB-231 and MCF-10A cells were determined by colorimetric assays using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] [58]. Cells were seeded (1×104 cells/100μL) into 96 well-plate (Greiner bio-one, 655180) and incubated until reaching 80% confluence. Afterwards, the cells were exposed to increasing concentrations of substances (3.12-100μM) for 48h. After treatment, the medium was removed, and cells were treated with MTT (1mg/mL) for 4h and formazan crystals were solubilized 100μL of DMSO. Absorbance was measured using an ELISA plate reader (spectrophotometer Labtech, LT-4000) at a wavelength of 540nm. Cytotoxicity assay was performed in comparison to the wells where the control cells (1% DMSO) were added instead of the tested compounds. Doxorubicin was used as a positive control of cell cytotoxicity [59].
Clonogenic assays
MDA-MB-231 (3×102/plate) were seeded into 6cm Petri dishes (Kasvi, K13-0060) and incubated at 37°C and 5% CO2 overnight (24h) and then treated with different concentrations (6.25, 12.5 and 15μM) of SSi6 and 6G for 48h. After this time, the culture medium was removed, and was replaced by complete culture medium (DMEM with 10% FBS) without treatment. The cells were maintained under the same conditions for a period of 10 days. After incubation, cells were fixed with methanol and acetic acid solution (3:1) for 5 min and stained with 0.5% crystal violet for 15 min. Colonies formed were analyzed in both number and size, using Image J software [28].
Detection of acid vesicular organelles (AVOs)
MDA-MB-231 and MCF-10A (1×104 cells/well) were seeded in a black 96 well-plate (Corning Costar, 3603) with a clear bottom and maintained at 37°C and 5% CO2 overnight. After incubation, cells were treated with SSi6 and 6G (25, 50 and 100μM) for 6h. After treatment, cells were washed with PBS and fixed with methanol for 10 min. Afterwards, cells were stained with acridine orange (AO; 1 μg/mL), which detects AVOs formation, for 15 min in the dark, then washed and stained with a solution of DAPI 1μg/mL (Life technologies, Carlsbad, CA), for nuclear staining, for 5min. Images were captured with automated high-resolution epifluorescence microscopy ImageXpress micro equipment (Molecular Devices, CA, USA) with a magnification of 400×. Rapamycin (500nM) and wortmannin (30μM) were used as a positive control for induction and inhibition of autophagy, respectively [28, 60].
Immunostaining
To determine the presence of LC3B protein after SSi6 and 6G treatment in MDA-MB-231 and MCF-10A, cells were incubated with anti-LC3B primary antibody specific for LC3B-I proteins (cytoplasmic protein) and LC3B-II (anchored to autophagossome membrane) was used. MDA-MB-231 and MCF-10A (1×104 cells/well) were seeded in a black 96 well-plate with a clear bottom (Corning Costar, 3603) and maintained at 37°C, 5% CO2 for 24h. Cells were exposed with 50μM of SSi6 and 100μM of 6G for 6h. Rapamycin (500nM) was used as the positive control of autophagy for 24h and for the negative control; cells were treated with 30μM wortmannin and added 50μM SSi6 for 6h of exposure. After treatment, the medium was removed, and cells were fixed with 4% paraformaldehyde (Sigma- Aldrich, P6148) for 20min and washed with PBS-glycine (50mM) (200μL) for 10min. After this, a block step was carried out for 1h with immunofluorescent solution (IF) + 10% bovine serum albumin (BSA; Sigma-Aldrich, A8412) in a buffer [(NaCl (1.30M), Na2HPO4 (0.13M), NaH2PO4 (0.029M), NaN3 (0.077M), Tween-20 (2% v/v) and Triton X-100 (0.5%), pH 7.4]. Subsequently, cells were incubated with anti-LC3B primary antibody (1:3000) for 3h at room temperature. Cells were washed three times with IF solution without BSA and incubated with a secondary antibody (Alexa Fluor® 488-conjugated goat to rabbit IgG) for 1h and stained with DAPI 0.5μg/mL for 4min. Images were obtained using an automated microscope ImageXpress® Micro XLS System (Molecular Devices) with a magnification of 400× and digital confocal adjust.
Apoptosis detection by flow cytometry
Apoptotic activity of SSi6 on MDA-MB-231 was analyzed by flow cytometry using the PE-Annexin-V Apoptosis Detection Kit (BD Bioscience, 559763). Cells (1×105 cells/well) were plated into 12 well-plates (Corning Costar, 3513) and after 24h of incubation at 37°C were exposed to different concentrations (25, 50 and 100μM) of SSi6 and 6G (100μM) during 6 and 14h. Cells were incubated with 5μL of PE-Annexin-V and 7-AAD for 15min in the dark. Analyses were performed in flow cytometer Accuri C6 (BD Bioscience, Franklin Lakes, NJ, USA) recording 10,000 events for each condition, after scraping the cells from the wells. Emitted fluorescence by each dye was quantified in CellQuest software (BD Bioscience, Franklin Lakes, NJ, USA), and it is proportional to the percentage of cells in apoptosis. The apoptotic rate of treatment was compared to the control (1% DMSO) and camptothecin (200μM) was used as the positive control of apoptosis [61].
Reverse transcriptase quantitative real time PCR (RT-qPCR)
A reverse transcriptase (RT)-polymerase chain reaction (PCR) was performed to evaluate changes in the mRNA expression. MDA-MB-231 cells (1×106/dish) were seeded into 6cm Petri dishes and after 24h of incubation, treated with SSi6 (25 and 50μM) and 6G (50 μM) for 1 and 10h. Total RNA was extracted using TRIzol reagent (Sigma-Aldrich, T9424). cDNAs were synthesized using the Enhanced Avian RT First Strand Synthesis kit (Sigma-Aldrich, STR1-1KT). Reactions were adjusted to each primer, depending on its melting temperature using Rotor Gene 6 software in Rotor-Gene RG 3000 equipment (Bio-Rad Laboratories, Hercules, CA, USA). In brief, 1μL of a reverse transcribed product template, 12.5μL of SYBR Green JumpStart Taq Ready Mix (Sigma-Aldrich, S4438) 10μL of pure water, 2μL of the primer pair and 0.5μL of cDNA at a final concentration 500nM made a final 25μL of the reaction system. The expression of genes related to apoptosis in treated cells was compared to control (1% DMSO). Primers used for amplification of MAP1LC3B, CASP3 and hAIF are described in Supplementary Table 1. For each gene, all samples were amplified simultaneously in duplicate in one assay run. Data represent three assays in duplicate and were normalized using the comparative cycle threshold (Ct) method. A blank with water, primers and SYBR Green instead of the template sample was performed. The target gene expression was normalized with endogen control Rpl37a, as previously described [62].
Western blotting
MDA-MB-231 cells (1×106/plate) were incubated for 24h with increasing concentrations of SSi6 (25, 50 and 100μM) and 6G (50 and 100μM) in Petri dishes (6cm) at 37°C. After incubation, cells were lysed using CelLytic™ M reagent (Sigma-Aldrich, St. Louis, MO, USA), according to the manufacturer's instructions in order to obtain the protein content. Protein concentrations of supernatants were determined using Pierce® BCA Protein Assay kit (Thermo scientific, 23225). Protein samples (15μg) were applied to 4-20% mini-PROTEAN® TGX™ Precast Gels (BioRad, 5871) for 1h at 100V, transferred to nitrocellulose membranes (BioRad, 1620145) and blocked with casein 1% (BioRad, 1610782) for 1h. All the processes followed the manufacturer's instructions. Next, the membranes were incubated overnight with anti-LC3B (1:3000), anti-Caspase-3 (1:1000) and anti-AIF (1:200) primary antibodies (Abcam, Cambrige, UK and Santa Cruz Biotechnology, Dallas, USA), followed by incubation with HRP-conjugated goat rabbit secondary antibody (1:5000) and for 1 h. β-actin was used as the endogenous control. Proteins were analyzed by chemiluminescence using Clarity™ Western ECL Substrate (BioRad, 1705060). Specific bands were visualized with a ChemiDoc MP imager (BioRad Laboratories, Hercules, CA, USA) and quantified with Image J software, normalized to β-actin antibody (1:3000) (Santa Cruz Biotechnology, sc-1616).
Reactive oxygen species (ROS) production
MDA-MB-231 and MCF-10A cells (1.5×105cells/well) were seeded in a 12-well plate and treated with different concentrations of SSi6 (25, 50 and 100μM) in the absence or presence of NAC (5mM) for 1 and 8h. After treatment, was added H2DCFDA [2′,7′-Dichlorodihydrofluorescein diacetate] (Sigma-Aldrich, D6883) was added at a concentration of 10μM for 30min before harvest. The fluorescence was measured using a Synergy H1 Hybrid Multi-Mode Microplate-Fluorimeter at a wavelength of λexcitation=400nm and λemission=525nm. ROS assay was performed compared to control cells (no treatment). Hydrogen peroxide (H2O2; Sigma-Aldrich, H1009) was used as a positive control (200μM) of production intracellular ROS [63, 64].
Mitochondrial membrane potential assay
The variation in mitochondrial membrane potential (ΔΨm) was investigated using BD™ MitoScreen Kit using the dye 5′.5′.6.6′- tetrachloro-1.1′.3.3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1; BD Bioscience, 551302). MDA-MB-231 cells (1×105cells/well) were seeded in a 12-well plate and treated with SSi6 (25, 50 and 100μM) for 8h of treatment. Afterwards, the mixture was incubated for 15 min with JC-1 (10μg/mL) in the dark. After incubation, the cells were washed twice with cold PBS, suspended in a total volume of 200μL and analyzed using a flow cytometer Accuri C6 (BD Bioscience, Franklin Lakes, NJ, USA) recording 10,000 events. During mitochondrial depolarization, JC-1 aggregates were dissociated to the monomer, which emitted green fluorescence in the cytoplasm during the decrease of mitochondrial membrane potential. Therefore, the changes of mitochondrial membrane potential were calculated as the ratio of red to green fluorescence [65]. Camptothecin at 200μM was used as the positive 521 control (8h incubation).
Small interfering RNA (siRNA)
The silencer predesigned siRNAs for LC3B (s37748 and s224886) and the non-target control siRNA (AM4611) were transfected into the MDA-MB-231 cells using DharmaFECT 4 (GE Healthcare, T-2004-01), at 25nM final concentration, according to the manufacturer's instructions. The lyophilized siRNAs were ressuspended in sterile ultrapure water. After 72h of cell transfection, apoptosis and western blotting assays were performed, as described previously in the Material and Methods section.
Statistical analysis
Each experiment was performed in triplicate and independently to guarantee the reliability and reproducibility of the results. Data were expressed as mean ± SD and statistical analyses were performed using one-way analysis of variance (ANOVA) (acceptable p level < 0.05), followed by Tukey's test, which compares all groups with control group. Analyses were performed using Microsoft Office Excel 2013 (Microsoft Corporation) and GraphPad Prism® version 6.0 (GraphPad Software, San Diego, CA, USA) software.
Authors: Lihong Wang; Liping Liu; Yan Shi; Hanwei Cao; Rupesh Chaturvedi; M Wade Calcutt; Tianhui Hu; Xiubao Ren; Keith T Wilson; D Brent Polk; Fang Yan Journal: PLoS One Date: 2012-05-04 Impact factor: 3.240
Authors: Chinmoy Sarkar; Zaorui Zhao; Stephanie Aungst; Boris Sabirzhanov; Alan I Faden; Marta M Lipinski Journal: Autophagy Date: 2014 Impact factor: 16.016
Authors: Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong Journal: Autophagy Date: 2021-02-08 Impact factor: 13.391